Ole Köhler-Forsberg

Ole Köhler-Forsberg

Auto-generated profile, based on publicly available information

Ole Köhler-Forsberg

Aarhus University Hospital

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2014 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
OKOle Köhler
Ole Köhler
MBMichael Eriksen Benros
Michael Eriksen Benros
MNMerete Nordentoft
Merete Nordentoft
MFMichael E. Farkouh
Michael E. Farkouh
RIRupa L. Iyengar
Rupa L. Iyengar
JKJesper Krogh
Jesper Krogh
Compelling evidence suggests that subgroups of major depressive disorder may be associated with an inflammatory state.1 Findings include elevated levels of cytokines2,3 and an increased susceptibility for autoimmune diseases and infections.4 Furthermore, treatment with proinflammatory agents induces symptoms of depression.5

26 August 2016 in Current Neuropharmacology
Verified
Journal Article
Open access
PDF file
OKOle Kohler
Ole Kohler
JKJesper Krogh
Jesper Krogh
OMOle Mors
Ole Mors
MBMichael Eriksen Benros
Michael Eriksen Benros
Accumulating evidence supports an association between depression and inflammatory processes, a connection that seems to be bidirectional. Clinical trials have indicated antidepressant treatment effects for anti-inflammatory agents, both as add-on treatment and as monotherapy. In particular, nonsteroidal anti-inflammatory drugs (NSAIDs) and cytokine-inhibitors have shown antidepressant treatment effects compared to placebo, but also statins, poly-unsaturated fatty acids, pioglitazone, minocycline, modafinil, and corticosteroids may yield antidepressant treatment effects. However, the complexity of the inflammatory cascade, limited clinical evidence, and the risk for side effects stress cautiousness before clinical application. Thus, despite proof-of-concept studies of anti-inflammatory treatment effects in depression, important challenges remain to be investigated. Within this paper, we review the association between inflammation and depression together with the current evidence on use of anti-inflammatory treatment in depression. Based on this, we address the questions and challenges that seem most important and relevant to future studies, such as timing, most effective treatment lengths and identification of subgroups of patients potentially responding better to different anti-inflammatory treatment regimens.

4 March 2019 in Acta Psychiatrica Scandinavica
Verified
Journal Article
Closed access
PDF file
OKOle Köhler‐Forsberg
Ole Köhler‐Forsberg
CLCecilie Nicolaisen Lydholm
Cecilie Nicolaisen Lydholm
CHCarsten Hjorthøj
Carsten Hjorthøj
MNMerete Nordentoft
Merete Nordentoft
OMOle Mors
Ole Mors
MBMichael Eriksen Benros
Michael Eriksen Benros

1 May 2017 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
OKOle Köhler-Forsberg
Ole Köhler-Forsberg
HBHenriette N. Buttenschøn
Henriette N. Buttenschøn
KTKatherine E. Tansey
Katherine E. Tansey
WMWolfgang Maier
Wolfgang Maier
JHJoanna Hauser
Joanna Hauser
OMOle Mors
Ole Mors

16 August 2018 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
SOSonja Orlovska-Waast
Sonja Orlovska-Waast
OKOle Köhler-Forsberg
Ole Köhler-Forsberg
SBSophie Wiben Brix
Sophie Wiben Brix
MNMerete Nordentoft
Merete Nordentoft
DKDaniel Kondziella
Daniel Kondziella
MBMichael Eriksen Benros
Michael Eriksen Benros
Infections and inflammatory processes have been associated with the development of schizophrenia and affective disorders; however, no study has yet systematically reviewed all available studies on cerebrospinal fluid (CSF) immune alterations. We aimed to systematically review the CSF immunological findings in schizophrenia spectrum and affective disorders. We identified all studies investigating CSF inflammatory markers in persons with schizophrenia or affective disorders published prior to March 23, 2017 searching PubMed, CENTRAL, EMBASE, Psychinfo, and LILACS. Literature search, data extraction and bias assessment were performed by two independent reviewers. Meta-analyses with standardized mean difference (SMD) including 95% confidence intervals (CI) were performed on case-healthy control studies. We identified 112 CSF studies published between 1942–2016, and 32 case-healthy control studies could be included in meta-analyses. Studies varied regarding gender distribution, age, disease duration, treatment, investigated biomarkers, and whether recruitment happened consecutively or based on clinical indication. The CSF/serum albumin ratio was increased in schizophrenia (1 study [54 patients]; SMD = 0.71; 95% CI 0.33–1.09) and affective disorders (4 studies [298 patients]; SMD = 0.41; 95% CI 0.23–0.60, I2 = 0%), compared to healthy controls. Total CSF protein was elevated in both schizophrenia (3 studies [97 patients]; SMD = 0.41; 95% CI 0.15–0.67, I2 = 0%) and affective disorders (2 studies [53 patients]; SMD = 0.80; 95% CI 0.39–1.21, I2 = 0%). The IgG ratio was increased in schizophrenia (1 study [54 patients]; SMD = 0.68; 95% CI 0.30–1.06), whereas the IgG Albumin ratio was decreased (1 study [32 patients]; SMD = −0.62; 95% CI −1.13 to −0.12). Interleukin-6 (IL-6) levels (7 studies [230 patients]; SMD = 0.55; 95% CI 0.35–0.76; I2 = 1%) and IL-8 levels (3 studies [95 patients]; SMD = 0.46; 95% CI 0.17–0.75, I2 = 0%) were increased in schizophrenia but not significantly increased in affective disorders. Most of the remaining inflammatory markers were not significantly different compared to healthy controls in the meta-analyses. However, in the studies which did not include healthy controls, CSF abnormalities were more common, and two studies found CSF dependent re-diagnosis in 3.2–6%. Current findings suggest that schizophrenia and affective disorders may have CSF abnormalities including signs of blood-brain barrier impairment and inflammation. However, the available evidence does not allow any firm conclusion since all studies showed at least some degree of bias and vastly lacked inclusion of confounding factors. Moreover, only few studies investigated the same parameters with healthy controls and high-quality longitudinal CSF studies are lacking, including impact of psychotropic medications, lifestyle factors and potential benefits of anti-inflammatory treatment in subgroups with CSF inflammation.

1 March 2019 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
OKOle Köhler-Forsberg
Ole Köhler-Forsberg
LPLiselotte Petersen
Liselotte Petersen
CGChristiane Gasse
Christiane Gasse
PMPreben B. Mortensen
Preben B. Mortensen
SDSoren Dalsgaard
Soren Dalsgaard
MBMichael Eriksen Benros
Michael Eriksen Benros
Previous studies1-3 of adults have indicated that severe infections are associated with an increased risk of mental disorders. Potential mechanisms include direct influences of infections in the central nervous system, immune activation, and inflammatory mediators,4,5 as well as alterations in the microbiome.6 A possible role for infection and inflammation in the pathogenesis of severe mental disorders is also supported by genetic studies7-9 documenting an increased risk associated with immune-regulatory genes.